曲美他嗪治疗冠心病心力衰竭患者121例临床分析

Clinical analysis of Trimetazidine in the treatment of 121 patients with coronary heart disease with cardiac failure

目的:探讨曲美他嗪治疗冠心病心力衰竭的临床效果。方法:121例2006年2月～2009年4月入住本院接受治疗的冠心病心力衰竭患者被随机分为实验组(n=63)和对照组(n=58),两组均给予常规治疗,实验组在常规治疗基础上给予曲美他嗪治疗。结果:对照组患者总有效率为70.7%(41/58),显效率为46.6%(27/58),实验组患者总有效率为95.2%(60/63),显效率为61.9%(39/63),差异具有统计学意义(P<0.05),另外两组的左心室舒张末径(LVEDD)、左心室收缩末内径(LVESD)、左心室射血分数(LVEF)等方面差异也有统计学意义(P<0.05),实验组疗效显著优于对照组。结论:曲美他嗪结合基础治疗应用于冠心病心力衰竭患者,能显著提高疗效,改善患者生活质量,值得在临床上应用和推广。

Objective： To explore the curative effect of trimetazidine in the treatment of coronary heart disease with cardiac failure. Methods： 121 cases of patients with coronary heart disease and cardiac failure were randomly divided into experimental group（n=63） and control group（n=58） from February 2006 to April 2009 in hospital for treatment. Both groups were given routine treatment,and experimental group were added to trimetazidine therapy on base of control group. Results： The total effective rate of experimental group was 70.7%（41/58）,excellent rate was 46.6%（27/58）,the data of control group was 95.2%（60/63） and 61.9%（39/63）,it showed significant difference（P〈0.05）. The LVEDD,LVESD and LVEF in two groups showed significant difference,too,the clinical effect of experimental group were significantly better than that of control group （P〈0.05）. Conclusion： trimetazidine combined with routine therapy used in coronary disease with cardiac failure patients can significantly enhance clinical effect and improve the life quality of patients,so it deserves application and promotion in clinical work.